Breaking News
March 23, 2019 - Study suggests depression screening when assessing African-Americans for schizophrenia
March 23, 2019 - New electronic support system for choosing drug treatment based on patient’s genotype
March 23, 2019 - First-of-its-kind study provides pregnancy statistics of imprisoned U.S. women
March 23, 2019 - Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
March 23, 2019 - Laparoscopy: MedlinePlus Lab Test Information
March 23, 2019 - Shellfish allergies: can they be treated?
March 23, 2019 - Toilet seat heart monitoring system
March 23, 2019 - Researchers identify way to improve common treatment for PTSD
March 23, 2019 - High potency cannabis use linked to psychosis finds study
March 23, 2019 - Evoke Pharma Submits Response to FDA Review Letter for Gimoti NDA
March 23, 2019 - Tracking HIV’s ever-evolving genome in effort to prioritize public health resources
March 23, 2019 - Scientists grow most sophisticated brain organoid to date
March 23, 2019 - ADHD drug raising risk of psychosis
March 22, 2019 - FDA approves brexanolone, first drug developed to treat postpartum depression
March 22, 2019 - Gruesome cat and dog experiments by the USDA exposed
March 22, 2019 - Ball pits used in children’s physical therapy may contribute to germ transmission
March 22, 2019 - Long-term use of inexpensive weight-loss drug may be safe and effective
March 22, 2019 - FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
March 22, 2019 - Anti-Müllerian Hormone Test: MedlinePlus Lab Test Information
March 22, 2019 - Finding the right exercise, diet aids for HIV patients
March 22, 2019 - Health Plans For State Employees Use Medicare’s Hammer On Hospital Bills
March 22, 2019 - Researchers develop new tool for imaging large groups of neurons in living animals
March 22, 2019 - Certain bacteria and immune factors in vagina may cause or protect against preterm birth
March 22, 2019 - Novel breath test could pave new way to non-invasively measure gut health
March 22, 2019 - Pharmaceutical and personal care products may result in new contaminants in waterways
March 22, 2019 - ACC: Catheter Ablation Does Not Cut Mortality, Stroke in A-Fib
March 22, 2019 - Wiedemann-Rautenstrauch syndrome – Genetics Home Reference
March 22, 2019 - Health insurance is not assurance of healthcare
March 22, 2019 - Supporting “curiosity-driven research” at the Discovery Innovation Awards
March 22, 2019 - Must-Reads Of The Week (Some Flying Below The Radar)
March 22, 2019 - Newly engineered nanoscale protein micelles can be tracked by MRI
March 22, 2019 - Mayo Clinic study identifies potential new drug therapy for liver diseases
March 22, 2019 - Pitt engineers win $550,000 NSF CAREER award to develop new intervention for people with ASD
March 22, 2019 - Early discharge does not increase readmission risk for patients after lung surgery
March 22, 2019 - Creating diverse pool of trained scientists to address Alzheimer’s research needs
March 22, 2019 - Surprising discovery offers clues to limit graft-vs.-host disease
March 22, 2019 - Study shows ACA’s positive impact on healthcare affordability and access for women
March 22, 2019 - Study provides new pathway for controlling inflammation
March 22, 2019 - New combination treatment shows promise for common brain tumor in children
March 22, 2019 - Virginia Tech Helmet Lab releases first youth-specific football helmet ratings
March 22, 2019 - New algae-based treatment could reduce need for limb amputation
March 22, 2019 - Stroke risk reduces in both black and white older Medicare beneficiaries, study reports
March 22, 2019 - City of Hope exhibits current studies and data on cancer therapies at AACR
March 22, 2019 - New study identifies CD40 molecule as key entry point for dangerous bacteria
March 22, 2019 - Health Tip: Six Steps to a Healthier Life
March 22, 2019 - even a little activity helps you live longer
March 22, 2019 - Many individuals recovering from addiction continue to suffer from chronic physical disease
March 22, 2019 - New drugs on PBS for Parkinson’s, MND and Cutaneous T cell lymphoma
March 22, 2019 - Saving energy also saves lives, UW-Madison study says
March 22, 2019 - Former inmates who receive social support have better mental health, study finds
March 22, 2019 - Nanofibrous membrane could enhance periodontal tissue regeneration
March 22, 2019 - Anti-vaxxer Italian leader down with chickenpox
March 22, 2019 - Servier collaborates with Harvard researchers to fight metabolic diseases
March 22, 2019 - National Eating Disorders Association
March 22, 2019 - Pumping up red blood cell production
March 22, 2019 - Excessive phosphate fertilizer may hurt plants by altering microbial composition in soil
March 22, 2019 - Medical marijuana laws could be improving older Americans’ health, study suggests
March 22, 2019 - Study indicates the benefits of stopping aspirin in heart attack patients
March 22, 2019 - Deep brain stimulation offers significant relief for patients with treatment-resistant depression
March 22, 2019 - Mental health problems in young adults on the rise
March 22, 2019 - Innovative membrane offers a viable solution for periodontitis
March 22, 2019 - The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI
March 22, 2019 - insulin therapy: MedlinePlus Medical Encyclopedia
March 22, 2019 - Guidelines on the use of genetic testing in psychiatry
March 22, 2019 - Aspiring Doctors Seek Advanced Training In Addiction Medicine
March 22, 2019 - A change in focus could enable the development of new treatments for Alzheimer’s disease
March 22, 2019 - A new way to visualize the immune cell “landscape” of bowel cancer tumors
March 22, 2019 - Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia
March 22, 2019 - Ludwig scientists to share advances in cancer research at AACR Annual Meeting 2019
March 22, 2019 - Less invasive valve replacement can be safe and effective alternative for healthier patients
March 22, 2019 - Aphasia research reveals new, complex interactions between thought and language
March 22, 2019 - Artificial neural networks can predict how different areas in the brain respond to words
March 22, 2019 - Age-related changes to gut microbiome have adverse impact on vascular health, study shows
March 22, 2019 - Study provides new insight into blood cell and immune cell production
March 22, 2019 - Isolated seniors chat online to prevent cognitive decline
March 22, 2019 - Repurposing drugs to outsmart cancers
March 22, 2019 - Naltrexone implant more effective in reducing relapses in HIV patients with opioid addiction
March 22, 2019 - The Brain Institute wins $7.04 million grant to investigate ‘neurophilosphy of free will’
March 22, 2019 - Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
March 22, 2019 - Eruptive xanthomatosis
InDevR releases first reagent kit for assessing neuraminidase in influenza vaccines

InDevR releases first reagent kit for assessing neuraminidase in influenza vaccines

image_pdfDownload PDFimage_print

InDevR Inc. announced product release of the first ever commercial reagent kit designed explicitly for assessment of neuraminidase (NA) in influenza vaccines. The new VaxArray kit is poised to help improve influenza vaccines by empowering manufacturers with a standardized method to meet current regulatory requirements and to prepare for future trends. The VaxArray NA kit is also expected to serve as an important new tool in the push for a more broadly protective or “universal” flu vaccine.

The level of neuraminidase (NA) in flu vaccines is not currently regulated but its “presence and type must be confirmed by suitable enzymatic or immunological methods” during vaccine manufacturing. Since no standardized method exits, vaccine producers each implement their own approach and many use non-influenza specific enzymatic activity assays. The VaxArray Influenza Seasonal NA kit is based on N1, N2, and B-NA subtype-specific monoclonal antibodies arrayed for use in a simple, multiplexed immunoassay. The assay is quantitative, highly correlated with enzymatic activity, stability indicating, and has been demonstrated to serve as a proxy for immunogenicity (see Vaccine 36 (2018) 2937-2945).

The VaxArray system has been evaluated by academic leaders who are working toward the ultimate goal of a universal flu vaccine. For example, Prof. Florian Krammer from the Department of Microbiology at the Icahn School of Medicine at Mount Sinai commented: “The VaxArray system is fast and easy to use. Since it is based on an immunoassay, the results are similar to ELISA in terms of specificity and sensitivity. However, the multiplexed microarray format provides substantially more information and higher throughput than ELISA-based assays. We believe that this system will be a valuable asset in helping us investigate the impact of NA in flu vaccines, including new universal flu vaccines.”

This view was echoed by Dr. Francesco Berlanda Scorza, PATH, Director of Vaccine Development: “PATH is working toward sustainable production of high-quality, affordable seasonal and pandemic influenza vaccines in developing countries with a focus on new low cost vaccines for children, including innovative broadly protective influenza vaccines. Improving our understanding the role of neuraminidase is an important component of this effort and we welcome advances to specifically measure neuraminidase content in new vaccine candidates. The new VaxArray NA reagent kit has the potential to greatly accelerate this effort.”

Vaccine industry leaders also see a need for better ways to assess the NA content in more traditional flu vaccines. According to Dr. Manon Cox, CEO of Next Wave Bio who led the development of the first recombinant influenza vaccine (Flublok®):

“As articulated by the focus group NAction! in a well-crafted position paper there many outstanding questions about the role neuraminidase in flu vaccines. For example, the level and quality of NA in vaccines can vary dramatically. Thus, one critical sticking point has been the lack of understanding the levels and stability of NA in flu vaccines as no standardized methods for the detection of NA exist. InDevR’s VaxArray assay for NA represents a major breakthrough that will enable unprecedented characterization of NA in both monovalent and multivalent vaccines.”

The VaxArray platform is expected to impact animal influenza vaccines as well. As described by Dr. Ben Hause, Vice President for Research and Development at Cambridge Technologies: “Advancements in flu vaccines for animals can happen quickly and we understand that neuraminidase could play an important role in enhancing flu vaccine effectiveness. This new potency assay for NA comes at just the right time and provides a much needed standardized method.”

Development of the VaxArray vaccine potency testing platform was supported in part by the Department of Health and Human Services’ (HHS) Influenza Vaccine Improvement Initiative through a Small Business Innovation Research grant R44AI102318 from the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health. HHS also sponsored a now-published study that demonstrated a predictive relationship between VaxArray-determined NA levels and vaccine-induced immunogenicity in mice through the Vaccine Manufacturing and Characterization Preclinical Services contract (HHSN272201200005I).

The first VaxArray Influenza Seasonal NA reagent kits are slated to ship on July 1st, 2018 and InDevR is now accepting advance purchase orders. InDevR also offers vaccine potency testing services. Find more information about the entire VaxArray product line at: https://indevr.com/products/vaxarray/

Tagged with:

About author

Related Articles